| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1006054747 |
| P356 | DOI | 10.1186/1878-5085-3-10 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1186/1878-5085-3-10 |
| P8608 | Fatcat ID | release_icqhpphrsfeefmwrhrxag7vqde |
| P932 | PMC publication ID | 3492156 |
| P698 | PubMed publication ID | 23016735 |
| P5875 | ResearchGate publication ID | 231223076 |
| P50 | author | Natalia Viktorovna Kokh | Q87385845 |
| P2093 | author name string | Maxim Leonidovich Filipenko | |
| Andrei Ivanovich Shevela | |||
| Andrei Pavlovich Momot | |||
| Elena Nikolaevna Voronina | |||
| Galina Alexandrovna Tsvetovskay | |||
| Galina Israilevna Lifshits | |||
| Liliya Alexandrovna Belozerceva | |||
| Valentin Viktorovich Vlasov | |||
| P2860 | cites work | Human homologue of maid: A dominant inhibitory helix-loop-helix protein associated with liver-specific gene expression | Q22254691 |
| CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant | Q24322624 | ||
| Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms | Q24554353 | ||
| Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 | Q28242581 | ||
| Identification of the gene for vitamin K epoxide reductase | Q28242592 | ||
| Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups | Q28395337 | ||
| A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose | Q28475004 | ||
| The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats | Q28576911 | ||
| Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians | Q31016306 | ||
| 10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal | Q33517162 | ||
| CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement | Q34026257 | ||
| Pharmacogenetics: potential for individualized drug therapy through genetics | Q34273202 | ||
| Common VKORC1 and GGCX polymorphisms associated with warfarin dose | Q34417386 | ||
| A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. | Q34418092 | ||
| Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose | Q34423204 | ||
| Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients | Q34571746 | ||
| CYP4F2 genetic variant alters required warfarin dose | Q34746151 | ||
| Association of warfarin dose with genes involved in its action and metabolism | Q35633802 | ||
| Promoting predictive, preventive and personalized medicine in treatment of cardiovascular diseases. | Q36117818 | ||
| Cardio-metabolic risk prediction should be superior to cardiovascular risk assessment in primary prevention of cardiovascular diseases | Q36117824 | ||
| Degenerative valve disease and bioprostheses: risk assessment, predictive diagnosis, personalised treatments | Q36117837 | ||
| A Japanese health success story: trends in cardiovascular diseases, their risk factors, and the contribution of public health and personalized approaches | Q36117855 | ||
| The future of warfarin pharmacogenetics in under-represented minority groups | Q36294461 | ||
| Pharmacogenomics: from bedside to clinical practice | Q36465177 | ||
| Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. | Q52005905 | ||
| Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. | Q52550127 | ||
| Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. | Q53257773 | ||
| Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort. | Q54606648 | ||
| Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications | Q63241969 | ||
| Detection of two missense mutations and characterization of a repeat polymorphism in the factor VII gene (F7) | Q68214111 | ||
| Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9 | Q71996232 | ||
| Molecular analysis of Polish patients with factor VII deficiency | Q72698886 | ||
| Influence of polymorphisms in the factor VII gene promoter on activated factor VII levels and on the risk of myocardial infarction in advanced coronary atherosclerosis | Q80534664 | ||
| Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose | Q80977030 | ||
| Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin | Q82627288 | ||
| The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement | Q83290003 | ||
| The pharmocogenomics of warfarin: closing in on personalized medicine | Q36588832 | ||
| The largest prospective warfarin-treated cohort supports genetic forecasting | Q37071087 | ||
| Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin | Q37087348 | ||
| Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin | Q37196787 | ||
| Warfarin sensitivity genotyping: a review of the literature and summary of patient experience | Q37454438 | ||
| Two common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration | Q38324973 | ||
| Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. | Q40442584 | ||
| Modulation of factor VII levels by intron 7 polymorphisms: population and in vitro studies. | Q40877503 | ||
| A cellular DNA-binding protein that activates eukaryotic transcription and DNA replication | Q41762670 | ||
| Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups | Q42253522 | ||
| A functional haplotype in the 5' flanking region of the factor VII gene is associated with an increased risk of coronary heart disease | Q42450936 | ||
| Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients | Q42734047 | ||
| VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China | Q42907084 | ||
| An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction | Q43055152 | ||
| A molecular mechanism for genetic warfarin resistance in the rat. | Q43771296 | ||
| The human factor VII gene is polymorphic due to variation in repeat copy number in a minisatellite | Q43777782 | ||
| Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. | Q44259188 | ||
| Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity | Q44680862 | ||
| A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. | Q45052744 | ||
| Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants | Q46463315 | ||
| Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. | Q46496005 | ||
| Warfarin dose related to apolipoprotein E (APOE) genotype | Q46542560 | ||
| Apolipoprotein E (APOE) and warfarin dosing in an Italian population | Q46679463 | ||
| Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing | Q46788661 | ||
| Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes | Q47961549 | ||
| Gamma-glutamyl carboxylase and its influence on warfarin dose. | Q49811574 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | anticoagulation | Q63279445 |
| P304 | page(s) | 10 | |
| P577 | publication date | 2012-09-27 | |
| P1433 | published in | The EPMA journal | Q26842213 |
| P1476 | title | Personalized approach of medication by indirect anticoagulants tailored to the patient-Russian context: what are the prospects? | |
| P478 | volume | 3 |
| Q36916966 | Personalized medicine and the clinical laboratory. | cites work | P2860 |
Search more.